Intelligence · Clinical Development
Pipeline search results
Programs matching “paclitaxel” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 72 pipeline programs matching "paclitaxel" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
B013+Nab-Paclitaxel
BRIGHT MINDS BIOSCIENCES INC.
Triple Negative Breast Cancer (TNBC)
1 trial -
BOOG 2010-02 Stop&Go study
Teva Pharma GmbH
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
1 trial -
Nab-paclitaxel 80 mg/m^2
CORCEPT THERAPEUTICS INC
Ovarian Neoplasm
1 trial -
Paclitaxel
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
Paclitaxel
Cellectar Biosciences
Non Small Cell Lung Cancer
1 trial -
Paclitaxel dosing according to SmPC
BRIGHT MINDS BIOSCIENCES INC.
Carcinoma, Non-Small-Cell Lung
1 trial -
Paclitaxel eluting PTCA balloon
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary In-stent Restenosis
1 trial -
Paclitaxel or docetaxel + Cisplatin or carboplatin
The First People's Hospital of Lianyungang
Uterine Cervical Neoplasms
1 trial -
Paclitaxel, Cisplatin Plus 5-FU (TCF)
The First People's Hospital of Lianyungang
Esophageal Cancer Stage IIB
1 trial -
Paclitaxel-releasing PTA balloon catheter
Lxo Ireland Designated Activity Company
Arteriovenous Fistula Renal Dialysis Devices Obstruction
1 trial -
nab-paclitaxel combined with carboplatin
The First People's Hospital of Lianyungang
Epithelial Ovarian Carcinoma Stage III
1 trial -
paclitaxel
United Therapeutics Europe Ltd
Germ Cell Tumor
1 trial -
paclitaxel/anthracycline
The First People's Hospital of Lianyungang
Primary Breast Cancer
1 trial -
13914704178
The First People's Hospital of Lianyungang
Locally Advanced Esophageal Squamous Cell Carcinoma
1 trial -
2020-S112
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Uterine Cervical Neoplasm
1 trial -
2024-HS-022
The First People's Hospital of Lianyungang
Platinum-sensitive Relapsed Ovarian Cancer
1 trial -
AK112-210
Akeso
Metastatic Pancreatic Ductal Adenocarcinoma
1 trial -
AZD5363 when combined with weekly paclitaxel.
AstraZeneca
Advanced or Metastatic Breast Cancer
1 trial -
Adebrelimab+Albumin paclitaxel +Cisplatin
The First People's Hospital of Lianyungang
Locally Advanced Hypopharyngeal Cancer
1 trial -
Afatinib and Paclitaxel
United Therapeutics Europe Ltd
Esophageal Cancer
1 trial -
Albumin Paclitaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Small Cell Lung Cancer
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer
1 trial -
Carboplatin plus Paclitaxel
United Therapeutics Europe Ltd
Ovarian Cancer
1 trial -
Cutting balloon followed by paclitaxel coated balloon
Hospital Authority, Hong Kong
Dialysis Access Malfunction
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.